Compare IPSC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | FDMT |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | 78 | 196 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.6M | 449.6M |
| IPO Year | 2021 | 2019 |
| Metric | IPSC | FDMT |
|---|---|---|
| Price | $2.27 | $8.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $4.25 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 644.7K | 580.4K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.30 | 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,164,000.00 | $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1556.76 | ★ 230194.60 |
| 52 Week Low | $0.44 | $3.37 |
| 52 Week High | $2.97 | $12.34 |
| Indicator | IPSC | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.15 | 40.74 |
| Support Level | $2.15 | $8.45 |
| Resistance Level | $2.41 | $8.80 |
| Average True Range (ATR) | 0.13 | 0.66 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 56.67 | 17.36 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).